AC5 Inhibitor for Obesity
Award amount
$133,845Program and phase
STTR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VASADE BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- J66DCHJSKWA4
- Solicitation number
- PHS2010-2
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
- Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
- Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
- AC5 inhibitor for heart failure
- AC5 inhibitor for heart failure
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
13 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $5,987,612. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services